EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
NOV 2024
-
EDITION 9
-
TABLES 123
-
REGIONS 26
-
SEGMENTS 8
-
PAGES 194
-
US$ 5450
-
MCP16287
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
HIGHLIGHTS & REPORT INDEX
Global Constipation Treatment Market to Reach US$27.5 Billion by 2030
The global market for Constipation Treatment estimated at US$18.4 Billion in the year 2023, is expected to reach US$27.5 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Laxatives, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$12.3 Billion by the end of the analysis period. Growth in the Chloride Channel Activators segment is estimated at 4.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 8.9% CAGR
The Constipation Treatment market in the U.S. is estimated at US$4.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.
Global Constipation Treatment Market – Key Trends & Drivers Summarized
Why Is There Increasing Demand for Constipation Treatment Solutions?
The growing prevalence of gastrointestinal disorders, particularly constipation, is driving demand for treatment solutions globally. Factors such as aging populations, sedentary lifestyles, poor dietary habits, and increasing levels of stress contribute to rising incidences of constipation, especially in developed regions. Moreover, constipation is a common side effect of medications used to treat chronic conditions like pain, hypertension, and diabetes. This has led to an increasing need for effective over-the-counter (OTC) laxatives, prescription medications, and natural remedies to alleviate symptoms and improve patients` quality of life.
How Are Technological and Pharmaceutical Innovations Impacting Constipation Treatment?
Pharmaceutical companies are continuously innovating to develop more effective and patient-friendly treatment options for constipation. Recent advancements include the development of novel laxatives with fewer side effects, such as osmotic laxatives, as well as medications like prokinetics that stimulate intestinal motility. Additionally, the rise of probiotics and fiber supplements as natural alternatives for managing constipation is gaining popularity, particularly among health-conscious consumers. Innovations in drug delivery mechanisms, such as extended-release formulations, are also helping to enhance treatment efficacy and patient compliance.
Which Demographic Segments Are Leading the Demand for Constipation Treatment?
The elderly population is a significant driver of demand for constipation treatments, as aging often leads to slower digestive function and increased reliance on medications that may cause constipation. Additionally, patients with chronic illnesses, such as irritable bowel syndrome (IBS), are frequent consumers of constipation treatment products. The increasing awareness of gastrointestinal health among younger populations is also fueling demand for OTC laxatives, natural remedies, and dietary supplements. Healthcare professionals are increasingly recommending preventive measures, including lifestyle modifications, to address chronic constipation, further driving the use of treatment solutions.
What Are the Key Growth Drivers of the Constipation Treatment Market?
The growth in the constipation treatment market is driven by several factors, including the increasing prevalence of gastrointestinal disorders, the growing aging population, and the rise in demand for OTC medications. The expanding awareness of digestive health and the rising trend toward self-medication are also boosting the demand for natural and OTC treatment options. Pharmaceutical advancements, such as the development of novel drugs with fewer side effects and more targeted action, are further contributing to market growth. Additionally, the increasing focus on preventive healthcare and lifestyle management is driving the adoption of dietary supplements and probiotics.
SCOPE OF STUDY
The report analyzes the Constipation Treatment market by the following Segments, and Geographic Regions/Countries:
Segments:
Disease Type (Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C), Opioid-Induced Constipation (OIC)); Therapeutic Option (Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists, 5-HT4 Receptor Agonists).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..
SELECT PLAYERS
Abbott; AbbVie`s Inc.; Albireo Pharma, Inc.; AstraZeneca; Bausch Health Companies Inc.; Bayer AG; Cosmo Pharma; Daewoong; Ironwood Pharmaceuticals; Janssen Pharmaceutical; Mallinckrodt Plc; Prestige Brands; Renexxion; Sanofi; Shionogi; Takeda Pharmaceutical Company Limited
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Constipation Treatment – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 41 Players Worldwide in 2024 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Growing Prevalence of Gastrointestinal Disorders |
Increasing Demand for Over-the-counter Laxatives and Natural Remedies |
Technological Advancements in Prescription Medications |
Rising Use of Probiotics and Fiber Supplements in Constipation Management |
Expanding Geriatric Population Driving Demand for Treatment Solutions |
Growing Awareness of Digestive Health and Preventive Care |
Increased Adoption of Combination Therapies for Chronic Conditions |
Rise in Demand for Home-based Constipation Treatment Products |
Rising Focus on Gut Health and Holistic Treatment Approaches |
Growing Popularity of Personalized Medicine in Constipation Treatment |
4. GLOBAL MARKET PERSPECTIVE |
World Constipation Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Constipation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Laxatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Chloride Channel Activators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Chloride Channel Activators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Chloride Channel Activators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Peripherally Acting Mu-Opioid Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Peripherally Acting Mu-Opioid Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Peripherally Acting Mu-Opioid Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for GC-C Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for GC-C Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for GC-C Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for 5-HT4 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for 5-HT4 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for 5-HT4 Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Chronic Idiopathic Constipation (CIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Chronic Idiopathic Constipation (CIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Chronic Idiopathic Constipation (CIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome with Constipation (IBS-C) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Irritable Bowel Syndrome with Constipation (IBS-C) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Irritable Bowel Syndrome with Constipation (IBS-C) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Opioid-Induced Constipation (OIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Opioid-Induced Constipation (OIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Opioid-Induced Constipation (OIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
USA Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
JAPAN |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
Japan Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
CHINA |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
China Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
EUROPE |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
Europe Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Constipation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
FRANCE |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
France Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
GERMANY |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
Germany Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
UNITED KINGDOM |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
UK Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Spain Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Russia Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
ASIA-PACIFIC |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Constipation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
AUSTRALIA |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E) |
Australia Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Australia Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
INDIA |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E) |
India Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
India Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
India Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
India Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
South Korea Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
LATIN AMERICA |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E) |
Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Constipation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Argentina Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Brazil Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Mexico Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
MIDDLE EAST |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E) |
Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Constipation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Iran Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Israel Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
UAE Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
AFRICA |
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E) |
Africa Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030 |
Africa Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com